Macroenzyme creatine kinase (CK) type 2 in HIV-infected patients is significantly associated with TDF and consists of ubiquitous mitochondrial CK

Antiviral Therapy

Volumn 11, Issue 8, 2006, Pages 1071-1080

  Schmid, Holger ^a   Mühlbayer, Dieter ^a   Röling, Jörg ^a   Sternfeld, Thomas ^a   Jülg, Boris ^a   Schlattner, Uwe ^b,c   Nelson, Peter J ^a   Bogner, Johannes R ^a   Wallimann, Theo ^b   Goebel, Frank D ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b ETH ZURICH   (Switzerland)

^c UNIV GRENOBLE ALPES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE BONE ISOENZYME; ASPARTATE AMINOTRANSFERASE; BETA 2 MICROGLOBULIN; CREATINE KINASE MB; DIDANOSINE; DOXORUBICIN; EFAVIRENZ; ETOPOSIDE; INDINAVIR; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MACROENZYME CREATINE KINASE TYPE 2; MITOCHONDRIAL CREATINE KINASE; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROTEINURIA;

EID: 33845630284     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Friis-Moller N, Sabin CA, Weber R, et al. Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993-2003.
2. Johnson RW, Williams FM, Kazi S, Dimachkie MM, Reveille JD. Human immunodeficiency virus-associated polymyositis: a longitudinal study of outcome. Arthritis Rheum 2003; 49:172-178.
3. Remaley AT, Wilding P. Macroenzymes: biochemical characterization, clinical significance, and laboratory detection. Clin Chem 1989; 35:2261-2270.
4. Greco FA. Identifying CK-MB and macro-CK by electrophoresis. Clin Chem 1987, 33:1954-1955.
5. Laureys M, Sion JP, Slabbynck H, et al. Macromolecular creatine kinase type 1: a serum marker associated with disease. Clin Chem 1991; 37:430-434.
6. Stein W, Bohner J, Bahlinger M. Analytical patterns and biochemical properties of macro creatine kinase type 2. Clin Chem 1985; 12:1952-1958.
7. Schlattner U, Tokarska-Schlattner M, Wallimann T. Mitochondrial creatine kinase in human health and disease. Biochim Biophys Acta 2006; 1762:164-180.
8. Lee KN, Csako G, Bernhardt P, Elin RJ. Relevance of macro creatine kinase type 1 and type 2 isoenzymes to laboratory and clinical data. Clin Chem 1994; 40:1278-1283.
9. Stein W, Bohner J, Renn W, Maulbetsch R. Macro creatine kinase type 2: results of a prospective study in hospitalized patients. Clin Chem 1985; 31:1959-1964.
10. Qin W, Khuchua Z, Cheng J, Boero J, Payne RM, Strauss AW. Molecular characterization of the creatine kinases and some historical perspectives. Mol Cell Biochem 1998; 184:153-167.
11. Fung HB, Stone EA, Piacenti FJ. Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection. Clin Ther 2002; 10:1515-1548.
12. Cihlar T, Birkus G, Greenwalt DE, Hitchcock MJ. Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors. Antiviral Res 2002; 54:37-45.
13. Schooley RT, Ruane P, Myers RA, et al. Study 902 Team. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 2002; 16:1257-1263.
14. Rosalski SB. An improved procedure for serum creatine phosphokinase determination. J Lab Clin Med 1967; 69:696-705.
15. Williams AL, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterology 1988; 95:734-739.
16. Levey A, Greene T, Kusek J, Beck G, MDRD Study Group. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000; 11:A0828.
17. Schlattner U, Mockli N, Speer O, Werner S, Wallimann T. Creatine kinase and creatine transporter in normal, wounded, and diseased skin. J Invest Dermatol 2002; 118:416-423.
18. Horster S, Jung C, Zietz C, Cohen CD, Siebeck M, Goebel FD. AIDS, multicentric Castleman's disease, and plasmablastic leukemia: report of a long-term survival. Infection 2004; 32:296-298.
19. Galarraga B, Sinclair D, Fahie-Wilson MN, McCrae FC, Hull RG, Ledingham JM. A rare but important cause for a raised serum creatine kinase concentration: two case reports and a literature review. Rheumatology (Oxford) 2003; 42:186-188.
20. Birkus G, Hitchcock MJM, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002, 46:716-723.
21. Barditch-Crovo P, Deeks SG, Collier A, et al. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2001; 45:2733-2739.
22. Shere-Wolfe KD, Verley JR. Marked elevation of the creatine phosphokinase level in a patient receiving tenofovir. Clin Infect Dis 2002; 35:1137.
23. Galasso PJ, Litin SC, O'Brien JF. The macroenzymes: a clinical review. Mayo Clin Proc 1993; 68:349-354.
24. Giannini E, Risso D, Botta F, et al. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med 2003; 163:218-224.
25. Karras A, Lafauri M, Furco A, et al. Tenofovir-related-nephrotoxicity in human immunodeficiency virus infected patients three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 2003; 36:1070-1073.
26. Mauss S, Berger F, Schmutz G. Antiretroviral therapy with tenofovir is associated with mild renal dysfunction. AIDS 2005; 19:93-95.
27. Anonymous. Viread (Tenofovir Disoproxil Fumarate) Product Monograph. Foster City, CA, USA: Gilead Sciences; 2001.
28. Parsonage MJ, Wilkins EG, Snowden N, Issa BG, Savage MW. The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy. HIV Med 2005; 6:341-346.
29. Lawlor DA, Zemmour J, Ennis PD, Parham P. Evolution of class-I MHC genes and proteins: from natural selection to thymic selection. Annu Rev Immunol 1990; 8:23-63.
30. Cabrera T, Lopez-Nevot MA, Gaforio JJ, Ruiz-Cabello F, Garrido F. Analysis of HLA expression in human tumor tissues. Cancer Immunol Immunother 2003; 52:1-9.
31. Miyata T, Jadoul M, Kurokawa K, Van Ypersele de Strihou C. Beta-2 microglobulin in renal disease. J Am Soc Nephrol 1998; 9:1723-1735.
32. Tsoukas CM, Bernard NF. Markers predicting progression of human immunodeficiency virus-related disease. Clin Microbiol Rev 1994; 7:14-28.
33. Hofmann B, Wang YX, Cumberland WG, Detels R, Bozorgmehri M, Fahey JL. Serum beta 2-microglobulin level increases in HIV infection: relation to seroconversion, CD4 T-cell fall and prognosis. AIDS 1990; 4:207-214.
34. Acchiardo S, Kraus AP Jr, Jennings BR. Beta 2-microglobulin levels in patients with renal insufficiency. Am J Kidney Dis 1989; 13:70-74.
35. Cihlar T, Birkus G, Greenwalt DE, Hitchcock MJ. Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors. Antiviral Res 2002; 54:37-45.
36. Schlattner U, Forstner M, Eder M, Stachowiak O, Fritz-Wolf K, Wallimann T. Functional aspects of the X-ray structure of mitochondrial creatine kinase: a molecular physiology approach. Mol Cell Biochem 1998; 184:125-140.
37. Payne RM, Strauss AW. Developmental expression of sarcomeric and ubiquitous mitochondrial creatine kinase is tissue-specific. Biochim Biophys Acta 1994; 1219:33-38.
38. Schlegel J, Wyss M, Schurch U, et al. Mitochondrial creatine kinase from cardiac muscle and brain are two distinct isoenzymes but both form octameric molecules. J Biol Chem 1988; 263:16963-16969.
39. Wallimann T, Hemmer W. Creatine kinase in non-muscle tissues and cells. Mol Cell Biochem 1994; 133-134:193-220.
40. Jacobus WE, Lehninger AL. Creatine kinase of rat heart mitochondria. Coupling of creatine phosphorylation to electron transport. J Biol Chem 1973; 248:4803-4810.
41. DiMauro S, Bonilla E, Zeviani M, Nakagawa M, DeVivo DC. Mitochondrial myopathies. Ann Neurol 1985; 17:521-538.
42. Saumoy M, Vidal F, Peraire J, et al. Proximal tubular kidney damage and tenofovir: a role for mitochondrial toxicity? AIDS 2004; 18:1741-1742.
43. Cote HC, Magil AB, Harris M, et al. Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy. Antivir Ther 2006; 11:79-86.
44. Tanji N, Tanji K, Kambham N, Markowitz GS, Bell A, D'agati VD. Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion. Hum Pathol 2001; 32:734-740.